The earnings call reflected a mix of positive and negative elements. The company highlighted strong growth in the Patient Direct business and improved EBITDA margins. However, challenges included significant costs associated with the Rotech acquisition termination and increased stranded costs, alongside slower-than-expected growth in the diabetes segment. Overall, the sentiment appears balanced with both positive and negative aspects influencing the outlook.

Company Guidance

During the Owens & Minor second-quarter 2025 earnings call, the company provided guidance for the full year, projecting revenue between $2.76 billion and $2.82 billion and adjusted EBITDA ranging from $376 million to $382 million, exclusive of the divested Products & Healthcare Services (P&HS) segment. The Patient Direct business, which is now the company's primary focus, demonstrated growth, with revenue for the quarter reaching $682 million, marking a 3.3% increase from the previous year. Adjusted EBITDA for Q2 was $96.6 million, reflecting a margin rate improvement from 13.8% to 14.2% compared to Q2 2024. Despite a lower-than-expected growth rate, partly due to supplier disruptions, the company anticipates a rebound in the diabetes category later in the year. Owens & Minor also highlighted a strong performance in sleep supplies, urology, and ostomy, attributing overall EBITDA growth to volume increases, improved collection rates, and a favorable product mix. Stranded costs, which impacted adjusted EBITDA, were $11 million for the quarter, with expectations of a rise following the anticipated near-term completion of the P&HS divestiture. The company plans to utilize the proceeds from the sale to reduce debt, targeting a leverage ratio of 2x to 3x EBITDA, while continuing to explore selective acquisition opportunities to bolster the Patient Direct business.

Patient Direct Business Growth

The Patient Direct business has grown significantly since its acquisition in 2017, with projected revenue between $2.76 billion and $2.82 billion and adjusted EBITDA range of $376 million to $382 million in 2025.

Adjusted EBITDA Improvement

For the second quarter, adjusted EBITDA was $96.6 million or 14.2% margin rate compared to $91.1 million or 13.8% margin rate in the second quarter of 2024, driven by volume growth, improved collection rate, favorable product mix, productivity gains, and lower benefit costs.

Strong Category Performance

Sleep, ostomy, and urology categories showed strong growth, with sleep supplies leading the overall growth rate.

Successful Cash Flow Management

Cash provided from operating activity in Q2 was $38 million, reversing the cash used in operating activity in Q1, driven by working capital reduction and improved collection rates.

Owens & Minor (OMI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OMI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.23 / -	0.42	―	―	―
Aug 11, 2025	2025 (Q2)	0.28 / 0.26	0.36	-27.78% (-0.10)
May 08, 2025	2025 (Q1)	0.20 / 0.23	0.19	21.05% (+0.04)
Feb 28, 2025	2024 (Q4)	0.52 / 0.55	0.69	-20.29% (-0.14)
Nov 04, 2024	2024 (Q3)	0.41 / 0.42	0.44	-4.55% (-0.02)
Aug 02, 2024	2024 (Q2)	0.33 / 0.36	0.18	100.00% (+0.18)
May 03, 2024	2024 (Q1)	0.18 / 0.19	0.05	280.00% (+0.14)
Feb 20, 2024	2023 (Q4)	0.66 / 0.69	0.28	146.43% (+0.41)
Nov 03, 2023	2023 (Q3)	0.38 / 0.44	0.41	7.32% (+0.03)
Aug 04, 2023	2023 (Q2)	0.18 / 0.18	0.76	-76.32% (-0.58)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OMI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$7.09	$4.63	-34.70%
May 08, 2025	$7.76	$6.99	-9.92%
Feb 28, 2025	$6.89	$9.58	+39.04%
Nov 04, 2024	$13.36	$12.00	-10.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.